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conclusion: IFN-g and TGF-b1 may be useful to identify AZA responders 
and IL8 and IL6 levels could be good predictors of response to both bio-
logical and immunosuppressive drugs. Our study is a first step for tailored 
therapy in IBD patients.
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Introduction: Measuring the concentration of infliximab drug levels in IBD 
patients is widely practiced. Variability between assays has previously 
been a problem as inconsistent results are obtained between different 
laboratories, depending on the methodology and manufacturer used. 
Introduction of the 1st International Standard infliximab material (NIBSC 
16/170) should allow for alignment of the methods for measuring inflix-
imab, and ultimately more consistent results between laboratories. 
Immundiagnostik has aligned the IDKmonitor® Infliximab drug level ELI-
SA by re-calibrating with the International Standard infliximab material 
(NIBSC 16/170). The impact of this change upon clinical results is explored.
aims & Methods: The aim of this work is to determine the change in the 
measured concentration of infliximab using the IDKmonitor® Infliximab 
drug level ELISA kit before and after alignment with the 1st International 
Standard infliximab (NIBSC 16/170).
Serum samples received through the routine infliximab monitoring service 
(n=80) were measured using the IDKmonitor® Infliximab drug level ELISA, 
using kits manufactured before and after calibration with the 1st Inter-
national Standard infliximab (NIBSC 16/170). Regression and correlation 
results were obtained.
results: Regression analysis of results before and after the calibration 
provide are good (R2 = 0.99). Correlation of the data shows that when 
aligned to the 1st International Standard infliximab (NIBSC 16/170), the 
measured concentration of infliximab is higher than that obtained with the 
kit manufactured before the calibration (i.e. post calibration result = 1.35x 
pre-calibration result + 0.81).
conclusion: International standardisation of infliximab drug level con-
centrations is now possible due to the introduction of the 1st International 
standard infliximab. This is a step change towards consistency of measur-
ing infliximab drug levels. 
However, clinicians who are using this test for monitoring need to be 
aware of this change and consider patient results carefully in the light of 
this information.
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Introduction: Oxidative stress is considered to play a pivotal role in the 
pathogenesis of Inflammatory Bowel Diseases (IBD). Serum free thiol 
groups (R-SH) reliably reflect systemic oxidative stress, since they are 
readily oxidized by reactive species. Endoscopic examination is the gold 
standard to determine disease activity in IBD. In clinical practice, fecal cal-
protectin (FC) levels are most widely used as surrogate marker for endo-
scopically proven disease activity. 
However, its diagnostic accuracy and applicability are still subject to de-
conclusion: Clinicians are well aware of the risk of POR in Crohn’s disease 
and tight endoscopic control within twelve months is often proposed. After 
a first ileocolonoscopy without POR, most respondents reported relying 
on fecal calprotectin for routine monitoring. The surprisingly high rate of 
immediate postoperative prophylactic therapy with biologics, even in the 
absence of clear endoscopic recurrence or clinical risk factors for POR, 
highlights the need for a randomized trial comparing immediate prophy-
laxis with endoscopy-driven therapy.
references: [1] Paolo Gionchetti, Axel Dignass, Silvio Danese, et al., on 
behalf of ECCO; 3rd European Evidence-based Consensus on the Diagnosis 
and Management of Crohn’s Disease 2016: Part 2: Surgical Management 
and Special Situations, Journal of Crohn’s and Colitis, Volume 11, Issue 2, 
1 February 2017, Pages 135-149 [2] Nguyen GC, Loftus EV Jr, Hirano I, et al., 
AGA Institute Clinical Guidelines Committee. American Gastroenterologi-
cal Association Institute Guideline on the Management of Crohn’s Disease 
After Surgical Resection. Gastroenterology. 2017 Jan;152(1):271-275
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Introduction: There is a rising interest in identifying easy to dose disease 
markers to predict response to therapy in inflammatory bowel disease 
(IBD) patients.
Several markers have been studied, but none of them has been validated.
aims & Methods: The aim of our study was to understand the role of in-
flammatory interleukins in predicting the response to immunosuppressive 
or biological therapy. A monocentric prospective study was conducted. 
Forty IBD patients who needed to start immunosuppressive or biologi-
cal drugs were included. For each patient serological levels of interleukin 
(IL)1-B, IL4, IL6, IL8, Il10, IL12p70, IL17, IFN-gamma, TNF-alfa, TGF-beta-1 
were dosed at the time of enrollment (T0) and after three months of im-
munosuppressive or biological therapy (T3). To dose these cytokines, mul-
tiplex Bio-Plex® system was used.
results: Among the 40 enrolled patients, 32 (80%) were suffering from 
Crohn’s disease (CD) and 8 from Ulcerative Colitis (UC); the mean age was 
46.6 years (18-79 years). 
IL1-B T0 was detectable only in CD patients (mean value 0.05 pg/ml), with 
no difference due to illness localization. 
Serological T0 TNF-a levels correlated with pre-treatment endoscopic ac-
tivity: among patients with moderate or severe endoscopical activity me-
dian value was 20.94 pg/ml while among mild activity or remission group 
median value was 13 pg/ml (p=0,034).
T0 IL8 levels correlated both with pre-treatment fecal calprotectin (p=0,03; 
r= 0.437) and endoscopic activity (median value 28,07 pg/ml for moderate 
to severe activity vs 5,79 pg/ml median value for mild activity/remission; 
p=0,023)
T0 TGF-b1 levels were significantly lower in CD patients than in UC patients 
(p = 0.0076). 
Low levels of IL6 at T0 (< =0.54 pg/ml) predicted a negativization of fecal 
calprotectin after three months of adalimumab (ADA) administration (area 
under the curve [AUC] = 0.89; p=0,001; sensitivity = 72.7%; specificity = 
100%). Low levels (median value = 0.54 pg/ml) of T0 IL6 correlated with 
a higher probability to response to azathioprine (AZA) too (p = 0.049). T0 
IL6 >=0.9 pg/ml correlated with higher response to vedolizumab (VEDO). 
Patients who responded to AZA had undetectable T0 serological levels of 
IFN-g, while the ones who did not respond had a median IFN-g level of 
0.11 pg/ml (p = 0.043). 
T0 serological levels of TGF-b1 correlated with response to AZA (< 4.7 pg/
ml) and to ADA (>6.57 pg/ml) (p = 0.027). 
Low IL12p70 levels predicted a better response to therapy at all (p = 
0.0095), but not for each drug separately. 
T0 IL8 levels predicted response to vedolizumab therapy: at ROC curve 
analysis we observed for >6,6 pg/ml levels of IL8 a response to VEDO in all 
patients (AUC = 1; sensitivity 100%; specificity 100%; p=0.0001).









































bate. Systemic biomarkers for disease activity are urgently sought to im-
prove disease activity monitoring and to avoid repeated endoscopic ex-
amination.
aims & Methods: In this study, we aimed to establish concentrations of 
serum free thiols in IBD and assessed their potential utility as a discrimi-
nating biomarker for different grades of endoscopic disease activity. Serum 
free thiol concentrations were measured in 78 IBD patients (31 patients 
with Crohn’s disease (CD) and 47 patients with ulcerative colitis (UC)) and 
50 healthy controls, adjusted for serum albumin. Albumin-adjusted serum 
free thiols were analyzed for associations with clinical and biochemical 
disease parameters. Endoscopic disease activity was assessed by the Sim-
ple Endoscopic Score for CD (SES-CD) and Mayo endoscopic subscore for 
UC, that were merged to create an IBD composite endoscopy score. Non-
parametric ROC estimation with cross-validated areas under the curves 
(AUCs) was used to assess the discriminative value of serum free thiols 
regarding the degree of endoscopic disease activity (n=54) and to com-
pare this to fecal calprotectin (n=28) in patients for which those data were 
available.
results: Mean serum free thiol concentrations were significantly decreased 
in both CD and UC as compared to healthy controls (19.4±3.1 and 17.8±3.4 
vs. 21.1±1.9 µmol/g of albumin, P < 0.001). Albumin-adjusted serum free 
thiols significantly inversely associated with age (r = -0.49, P < 0.01), plate-
let counts (r = -0.29, P < 0.01) and fecal calprotectin levels (r = -0.32, P 
< 0.05). Patients with severe endoscopic disease activity demonstrated 
significantly lower serum free thiol concentrations compared to patients 
having mild disease activity (16.2±3.1 vs. 20.4±3.4 µmol/g of albumin, P < 
0.01). Finally, serum free thiols highly accurately discriminated between 
mild and moderate-to-severe disease activity, better than fecal calprotec-
tin (FC) levels (AUC=0.87, P < 0.001 vs. AUC=0.76, P < 0.05, respectively). 
After cross-validation, serum free thiols maintained their predictive ac-
curacy (AUC=0.89, P < 0.001).
conclusion: Serum free thiols are reduced in IBD as compared to healthy 
controls and strongly correlate with the degree of endoscopic disease ac-
tivity. Quantifying systemic redox status in IBD may be a promising, mini-
mally invasive strategy to monitor IBD disease activity. Future studies are 
warranted to further explore free thiols as potential biomarker for IBD 
disease activity in larger, prospective patient cohorts and serially assess 
their predictive value in relation to disease course and therapeutic inter-
ventions.
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Introduction: Diagnosis of inflammatory bowel disease (IBD) require com-
bination of patient history and physical examination in association with 
laboratory, endoscopic, histologic, and radiographic investigations. Al-
though ileocolonoscopy is the preferred method of diagnosis, assessing 
disease extent, activity and follow up after therapy but repeated endoscopy 
is neither practical nor feasible, being invasive, time consuming, and not 
always well tolerated or accepted. 
Therefore, employment of non-invasive biomarkers is needed. No single 
marker is ideal. Many studies focus on fecal calprotectin (FC) in IBD and 
confirm its value in diagnosis, disease activity evaluation, effect evalua-
tion, and relapse monitor.
Neopterin, is a metabolite of cyclic guanosine monophosphate that is re-
leased by activated T lymphocytes and macrophages after induction by 
interferon γ. Neopterin release from activated macrophages may provide, 
at least theoretically by its intrinsic mechanism of release, an advantage 
over calprotectin which is not secreted and represents a neutrophil-de-
rived protein.
aims & Methods: ts specificity and sensitivity to To investigate the relation 
between fecal neopterin (fNeo) excretion and IBD clinical and endoscopic 
activity indices and compare its specificity to that of fecal calprotectin.
60 patients were included: 30 patients with ulcerative colitis (UC) (15 clini-
cally in remission, 15 active ) and 30 patients with Crohn’s disease (CD) (15 
clinically in remission, 15 active ) and 20 healthy control subjects. 
FC and fNeo were detected in stool samples by enzyme-linked immuno-
sorbent assay (ELISA).
The following indices were calculated at enrollment: for Crohn’s disease 
the Crohn’s disease activity index (CDAI) and simple endoscopic score for 
Crohn’s disease (SES-CD); for ulcerative colitis, Simple Clinical Colitis Activ-
ity Index (SCCAI) and ulcerative colitis endoscopic index of severity (UCEIS).
results: Among UC patients, fNeo was higher in those with either clini-
cally active or inactive disease than in control subjects ( P=0.001, P=0.040 
; for active and inactive disease vs. controls respectively) but there was no 
significant difference between both UC groups (P=0.225). For CD patients, 
fNeo concentration was higher in those with active disease than in those 
with inactive diseas (P< 0.001) or healthy controls (P=0.001). Nonsignifi-
cant trends toward greater fecal neopterin concentration were observed 
with increased colonic disease involvement. Neopterin was not found to 
be significantly correlated with all laboratory tests done (Heamoglobin, 
platelets, white blood cells, ESR, CRP, serum albumin, fecal calprotectin). 
fNeo was significantly correlated with CDAI (r=0.604, P< 0.001) , SES-CD 
(r=0.600, P< 0.001) in CD patients but not with SCCAI, UCEIS in UC patients. 
fNeo was found to have comparable sensitivity and overall accuracy to FC 
in predicting endoscopic disease activity in CD patients but less in UC and 
combing both stool tests together increases the sensitivity and specificity 
of either alone.
conclusion: Stool neopterin could be used to assess disease activity in CD 
but not in UC patients as it correlates positively with disease activity indi-
ces in CD but not in UC. Thus its measurement represents a novel reliable 
biomarker useful to detect and monitor the severity of mucosal affection in 
CD patients more than UC.
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